Remdesivir (new indication: COVID-19, patients not requiring supplemental oxygen, with increased risk of progressing to severe COVID-19)

Subject:

• Active Substance: Remdesivir
• Name: Veklury^®
• Therapeutic area: Coronavirus disease 2019 (COVID-19)
• Pharmaceutical company: Gilead Sciences GmbH

Time table:

• Start: 15.01.2022
• Final decision by G-BA: 07.07.2022

Final decision:

• Hint for a minor additional benefit